PRC2/EED Polycomb Repression Complex 2/Embryonic Ectoderm Development

Cat.No.	Name	Information
M11244	A-395	A-395 is A Polycomb inhibitory complex 2 (Polycomb repressive complex 2; PRC2), a protein-protein interaction antagonist, inhibits the trimer PRC2 complex (ezh2-EED -SUZ12) with an IC50 value of 18 nM.
M6163	MAK683	MAK-683 is a potent inhibitor of embryonic ectoderm development protein (EED) and allosteric inhibitor of polycomb repressive complex 2 (PRC2).
M5243	EED226	EED226 is an effective, selective and orally active Polycomb reactive complex 2 (PRC2) inhibitor. When h3k27me0 peptide is used as substrate, ic50=23.4 nm; With mononucleosome as substrate, ic50=53.5 nm. It is a first in class, effective, orally bioavailable inhibitor of embryonic ectodermal development (EED) with strong anticancer effect.
M11356	EEDi-5285	Eedi-5285 is a highly effective and orally active inhibitor of embryonic ectodermal development (EED). The IC50 value of BINDING EED protein is 0.2 nM, and it has anticancer activity.
M11355	EEDi-5273	Eedi-5273 is a potent and orally effective EED inhibitor (IC50 = 0.2 nM) that can achieve complete and sustained tumor regression.
M11015	FTX-6058	FTX-6058 is a potent, orally active embryonic ectodermal development (EED) inhibitor. FTX-6058 can induce HbF protein expression in both cell and murine models. FTX-6058 can be used in the study of specific hemoglobinopathies, including sickle cell disease and β-thalassemia.